Clinical trial
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING).
NCT05583227 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING).
- Lead sponsor
- AstraZeneca
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- November 10, 2022
- Completion date
- March 23, 2027
- Enrollment
- 368 (actual)
- Sites
- 124
Conditions
As the registry lists them; a condition with its own page is linked.